Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.33 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.33 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.33 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.33 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.33 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.33 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.33 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 4/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26829174 | 0.99 | LGALS8 (0.39) | LGALS8LGALS3LGALS4PTPN1ATP1A1 | |
| SCHEMBL25839392 | 0.84 | LGALS3 (0.40) | LGALS8LGALS3LGALS4PTPN1ATP1A1 | |
| SCHEMBL23685943 | 0.82 | LGALS8 (0.35) | LGALS8LGALS3LGALS4ATP1A1ATP1B1 | |
| SCHEMBL27048068 | 0.80 | ATP1A1 (0.40) | LGALS8LGALS3LGALS4PTPN1ATP1A1 | |
| SCHEMBL25839647 | 0.79 | GAA (0.51) | LGALS8LGALS3LGALS4PTPN1GAA | |
| SCHEMBL16144536 | 0.79 | LGALS3 (0.43) | LGALS8LGALS3LGALS4PTPN1GAA | |
| SCHEMBL7772026 | 0.75 | GBA2 (0.35) | LGALS8LGALS3GAA | |
| SCHEMBL15145344 | 0.75 | GBA2 (0.35) | LGALS8LGALS3GAA | |
| SCHEMBL22640981 | 0.75 | GBA2 (0.35) | LGALS8LGALS3GAA | |
| SCHEMBL21479622 | 0.75 | GBA2 (0.35) | LGALS8LGALS3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833170-B2 | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230302041-A1 | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents | SCOTT, JOHN KIM, JR. | 2023-09-28 | — | — | US | disclosed |
| US-20230248757-A1 | Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking | SCOTT, JOHN KIM, JR. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248757-A1 | Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking | CD209, FUT6, SIGLEC7 | LGALS8 120/4885LGALS3 73/4885LGALS4 64/4885 |
| US-11833170-B2 | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking | CD209, FUT6, SIGLEC7 | LGALS8 120/4885LGALS3 73/4885LGALS4 64/4885 |
| US-20230302041-A1 | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents | MANBA, MAN2B2, MAN2B1 | LGALS8 91/4885LGALS3 135/4885LGALS4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.